170 related articles for article (PubMed ID: 16459649)
1. [Zoledronic acid and bone pathology in the course of neoplasia. Part I].
Caffo O
Tumori; 2005; 91(5):22-6. PubMed ID: 16459649
[No Abstract] [Full Text] [Related]
2. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
McKeage K; Plosker GL
Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
[TBL] [Abstract][Full Text] [Related]
3. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
Morgan GJ; Davies FE; Gregory WM; Cocks K; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross F; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Child JA;
Lancet; 2010 Dec; 376(9757):1989-99. PubMed ID: 21131037
[TBL] [Abstract][Full Text] [Related]
4. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient.
Mishra A
J Postgrad Med; 2008; 54(3):237. PubMed ID: 18626181
[No Abstract] [Full Text] [Related]
5. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
Barrett-Lee P; Casbard A; Abraham J; Hood K; Coleman R; Simmonds P; Timmins H; Wheatley D; Grieve R; Griffiths G; Murray N
Lancet Oncol; 2014 Jan; 15(1):114-22. PubMed ID: 24332514
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid: a review of its use in breast cancer.
Lyseng-Williamson KA
Drugs; 2008; 68(18):2661-82. PubMed ID: 19093706
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
Dhillon S; Lyseng-Williamson KA
Drugs; 2008; 68(4):507-34. PubMed ID: 18318568
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates in breast cancer.
Coleman RE
Ann Oncol; 2005 May; 16(5):687-95. PubMed ID: 15802276
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic agents for disorders of bone and calcium metabolism: Zoledronic acid].
Sakurai T
Clin Calcium; 2007 Jan; 17(1):24-8. PubMed ID: 17211090
[TBL] [Abstract][Full Text] [Related]
11. Annual zoledronic acid: is less more?
Higano CS
J Clin Oncol; 2007 Mar; 25(9):1026. PubMed ID: 17369565
[No Abstract] [Full Text] [Related]
12. [Bisphosphonates for osseus invasion caused by bronchial carcinoma].
Bartl R
Dtsch Med Wochenschr; 2008 Nov; 133(48):2530. PubMed ID: 19021088
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients.
Paterson A; McCloskey E; Redzepovic J; Ott I; Gust R
J Int Med Res; 2008; 36(3):400-13. PubMed ID: 18534121
[TBL] [Abstract][Full Text] [Related]
14. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
Barrett-Lee P; Bloomfield D; Dougherty L; Harries M; Laing R; Patel H; Walker M
Curr Med Res Opin; 2007 Jul; 23(7):1575-82. PubMed ID: 17559749
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
16. [Bisphosphonates in adjuvant therapy of breast cancer].
Deuber HJ; Theiss F
Med Klin (Munich); 2010 Sep; 105(9):635-46. PubMed ID: 20878301
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid in the treatment of metastatic breast cancer.
Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
[TBL] [Abstract][Full Text] [Related]
19. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.
Morgan GJ; Child JA; Gregory WM; Szubert AJ; Cocks K; Bell SE; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Wu P; Davies FE;
Lancet Oncol; 2011 Aug; 12(8):743-52. PubMed ID: 21771568
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
